{
  "docId": "019de072-4729-7396-8f8e-eb3955e66e61",
  "docSlug": "7286daabf487d40c2a70ede12061c49a",
  "documentTitle": "Apexigen | SPAC Presentation Deck | 28 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 28,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a three-column layout for key business pillars supported by a central platform foundation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4729-7396-8f8e-eb3955e66e61/7",
  "deckHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61",
  "deckJsonHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61.json",
  "deckAnchorHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.52,
        "x": 0.24,
        "y": 0.067
      },
      "kind": "callout",
      "text": "VALIDATED APXiMAB™ ANTIBODY DISCOVERY PLATFORM",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8f6adb7-0363-492b-aa9c-ae8dc68727a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.26,
        "x": 0.37,
        "y": 0.11
      },
      "kind": "image",
      "text": "Apexigen",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c9505c2-77f4-448a-a009-c9a54c176af6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.26,
        "x": 0.65,
        "y": 0.035
      },
      "kind": "list",
      "text": "VALIDATING PARTNERSHIPS: 5 Licensees, Ocular disease BLA: 1st US approval for product derived from APXiMAB",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28c7cbf7-1b98-4812-a19e-e6f1dbcad6be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.26,
        "x": 0.09,
        "y": 0.035
      },
      "kind": "list",
      "text": "LEAD PRODUCT: Sotigalimab/APX005M, Potentially first-in-class and best-in-class CD40 agonist with validating data & near-term milestones",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d547ddf3-8cc6-477d-9e63-4f2436c4f843",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.26,
        "x": 0.37,
        "y": 0.035
      },
      "kind": "list",
      "text": "PROPRIETARY PIPELINE: 2 Product Candidates, APX601 TNFR2: IND mid'22, APX801 NK cell engager, Additional research programs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff953914-16be-40f0-a022-cb03f5ccf1fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.086
      },
      "kind": "metric",
      "text": "$158M Equity Financing to Date",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3703cd30-76ed-4d5d-aef2-a719ea612641",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.55,
        "y": 0.086
      },
      "kind": "metric",
      "text": "Multiple Near-term Milestones",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afe53ad5-efd3-4cf8-94dc-96a0bb162e70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "title",
      "text": "Leader in Discovering and Developing Innovative Therapeutic Antibodies Against Cancer",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "179bd7fb-75c5-40c5-bc9e-ce4a61541636",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "06d40e20-366a-46c6-bc1a-dac4706454ab",
      "evidence": "The slide follows the AIDA model (Attention, Interest, Desire, Action) by grabbing attention with a bold title, generating interest with key product and pipeline information, creating desire with validating partnerships, and prompting action with near-term milestones and equity financing.",
      "confidence": 0.7
    },
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "febef505-169e-4844-ac9f-4e14cea90cd9",
      "evidence": "This slide serves as an executive summary, providing a concise overview of the company's key points, including lead product, proprietary pipeline, validating partnerships, and key metrics.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 7,
      "beatId": "ecbe4e76-7700-4b1c-9c52-a7802f904770",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The executive summary highlights the need for innovative therapeutic antibodies against cancer.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 7,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "398acacc-ee0a-4473-8f0c-104232e4369b",
      "evidence": "The executive summary emphasizes the importance of addressing cancer.",
      "position": 0,
      "objective": "Highlight the need for innovative cancer treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}